Alternative pharmacological strategies for adult ADHD treatment: a systematic review
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Adult Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent psychiatric condition associated with high disability and frequent comorbidity. Current standard pharmacotherapy (methylphenidate and atomoxetine) improves ADHD symptoms in the short-term, but poor data were published about long-term treatment. In addition a number of patients present partial or no response to methylphenidate and atomoxetine. Research into the main database sources has been conducted to obtain an overview of alternative pharmacological approaches in adult ADHD patients. Among alternative compounds, amphetamines (mixed amphetamine salts and lisdexamfetamine) have the most robust evidence of efficacy, but they may be associated with serious side effects (e.g. psychotic symptoms or hypertension). Antidepressants, particularly those acting as noradrenaline or dopamine enhancers, have evidence of efficacy, but they should be avoided in patients with comorbid bipolar disorder. Finally metadoxine and lithium may be particularly suitable in case of comorbid alcohol misuse or bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928 · cited 1×
“[2] Untreated adult ADHD has been associated with important social problems including more unemployment, criminality and suicidal attempts than general population.[3] From a biological point of view, a deficiency in dopaminergic neurotransmission, particularly between prefrontal and striate centers, is thought to be a…”
BackgroundSharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Arnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383 · cited 2×
“Guanfacine is a selective agonist of α2A noradrenergic receptor that is supposed to ameliorate symptoms of ADHD patients in whom a disruption of these receptors in prefrontal cortex has been observed.[77] A very small-sample double-blind cross-over study showed that guanfacine (mean dose 1.”
BackgroundKessler, R. C., Green, J. G., Adler, L. A., Barkley, R. A., Chatterji, S., Faraone, S. V., Finkelman, M., Greenhill, L. L., Gruber, M. J., Jewell, M., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.146 · Cited by 317
Shaw, P., Malek, M., Watson, B., Greenstein, D., de Rossi, P., & Sharp, W. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.007 · Cited by 303
A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272 · cited 1×
“400 mg/day in improving ADHD symptoms.[37] These positive results have been confirmed by a small-sample single-blind trial [38], a large randomized placebo-controlled study with high dose of bupropion (450 mg/day) [40] and a further recent double-blind placebo-controlled trial with a predominantly male sample.”
ResultSpencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250 · cited 1×
“group.[15] These results were confirmed by a subsequent 4-week double-blind placebo controlled trial with 255 ADHD patients treated with different doses”
ResultThe Dopamine Theory of Attention Deficit Hyperactivity Disorder (ADHD)
Levy, F. (1991) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679109077746 · Cited by 234 · cited 1×
“[3] From a biological point of view, a deficiency in dopaminergic neurotransmission, particularly between prefrontal and striate centers, is thought to be associated with ADHD symptoms.[4] In support of this hypothesis, studies have found an association of ADHD with polymorphisms of dopamine type 4 receptors and dopam…”
Result(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228
Gender differences in adults with attention-deficit/hyperactivity disorder: A narrative review
Williamson, D., & Johnston, C. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.05.005 · Cited by 226
Cited by
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Pharmacological and non-pharmacological treatment of adults with ADHD: A meta-review
De Crescenzo, F., Cortese, S., Adamo, N., & Janiri, L. (2017) · Evidence Based Mental Health · doi:10.1136/eb-2016-102415 · Cited by 150
Abdi Dezfouli, R., Akbariforoud, S., & Esmaeilidezfouli, E. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00405-w · Cited by 4
“In line with our study, Buoli et al. (2016) [49] conducted a systematic review of alternative pharmacological strategies for ADHD.”
BackgroundResultInfluential
Metadata
- Authors
- Buoli, M., Serati, M., & Cahn, W.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2016-01-14
- Volume
- 16
- Issue
- 2
- Pages
- 131-144
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2252072392
- Cited by
- 46
- References
- 29
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alternative pharmacological strategies for adult ADHD treatment: a systematic review. https://app.cochat.ai/papers/10.1586/14737175.2016.1135735
- The paper
- Buoli, M., Serati, M., & Cahn, W. (2016). Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2016.1135735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.